Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a proven benefit in terms of higher response rate, delaying...

Descripción completa

Detalles Bibliográficos
Autores principales: Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J., Mulatero, C., Subramanian, S., Thomas, A., Thatcher, N., Nicolson, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532717/
https://www.ncbi.nlm.nih.gov/pubmed/26187773
http://dx.doi.org/10.1007/s40265-015-0434-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532717/
https://www.ncbi.nlm.nih.gov/pubmed/26187773
http://dx.doi.org/10.1007/s40265-015-0434-6

Ejemplares similares